A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor.

von Sibilia, M, Steinbach, J P, Stingl, L, Aguzzi, A, Wagner, E F
Veröffentlicht 1998

Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas

von Wenger, K.J., Steinbach, J.P., Bähr, O., Pilatus, U., Hattingen, E.
Veröffentlicht in AJNR Am J Neuroradiol (2020)

P10.04 Anti-angiogenetic Therapy with Bevacizumab for Gliomas with a Gliomatosis Cerebri Growth Pattern

von Burger, M. C., Mildenberger, I. C., Wagner, M., Mittelbronn, M., Steinbach, J. P.
Veröffentlicht in Neuro Oncol (2017)

P01.10 METABOLIC CONDITIONS DETERMINE SENSITIVITY OF GLIOMA CELLS AGAINST EPIDERMAL-GROWTH FACTOR RECEPTOR (EGFR)-INHIBITION

von Hartel, I.A., Wolking, S., Wanka, C., Ronellenfitsch, M.W., Steinbach, J.P., Rieger, J.
Veröffentlicht 2014

P01.11 The transcriptional coactivator PGC-1a promotes defence against reactive oxygen species (ROS) and proliferation in human glioma cells

von Hartel, I., Sauer, B., Burger, M., Ronellenfitsch, M. W., Steinbach, J. P., Rieger, J.
Veröffentlicht in Neuro Oncol (2016)

P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy st...

von Steidl, E., Pilatus, U., Steinbach, J. P., Zanella, F., Ronellenfitsch, M. W., Hattingen, E., Bähr, O.
Veröffentlicht in Neuro Oncol (2016)

OS1.4 Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy

von Foltyn, M., Thiepold, A., Harter, P. N., Baumgarten, P., Mittelbronn, M., Urban, H., Steinbach, J. P., Ronellenfitsch, M. W.
Veröffentlicht in Neuro Oncol (2016)

P04.24 MTOR signaling in glioma-associated microglia and macrophages

von Zeiner, P S, Lorenz, N I, Burger, M, Luger, A L, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Veröffentlicht in Neuro Oncol (2018)

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

von Strassheimer, F, Zhang, C, Mildenberger, I C, Harter, P N, Tonn, T, Steinbach, J P, Wels, W S, Burger, M C
Veröffentlicht in Neuro Oncol (2018)

P04.47 Nrf2 mediates hypoxic tolerance in human glioblastoma cells

von Lorenz, N I, Luger, A, Zeiner, P S, Engel, A L, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Veröffentlicht in Neuro Oncol (2018)

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

von Burger, M.C., Zhang, C., Jennewein, L., Schönfeld, K., Genßler, S., Grez, M., Tonn, T., Mittelbronn, M., Steinbach, J.P., Wels, W.S.
Veröffentlicht 2014

P16.11 Complete resection is not associated with improved survival in MGMT non-methylated glioblastoma. Results from the GLARIUS trial

von Kebir, S., Stummer, W., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Proescholdt, M., Vatter, H., Herrlinger, U., Glas, M.
Veröffentlicht in Neuro Oncol (2017)

P01.03 mTORC1 activation sensitizes human malignant glioma cells to hypoxia-induced cell death by increasing O2-consumption

von Thiepold, A. L., Foltyn, M., Urban, H., Heller, S., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Veröffentlicht in Neuro Oncol (2016)

P01.101 Treatment and survival of patients with lower grade glioma according to the 2007 and the 2016 WHO classification: A retrospective analysis of 423 patients.

von Steidl, E, Zeiner, P, Wagner, M, Fokas, E, Forster, M, Ronellenfitsch, M, Steinbach, J P, Harter, P N, Bähr, O
Veröffentlicht in Neuro Oncol (2018)

O10.04 THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL...

von Herrlinger, U., Schäfer, N., Steinbach, J.P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.
Veröffentlicht 2014

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

von Burger, M. C., Mildenberger, I., Zhang, C., Ihrig, K., Wagner, M., Mittelbronn, M., Senft, C., Tonn, T., Wels, W. S., Steinbach, J. P.
Veröffentlicht in Neuro Oncol (2016)

P01.31 Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death

von Thiepold, A., Foltyn, M., Urban, H., Voss, M., Hofmann, U., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Veröffentlicht in Neuro Oncol (2017)

P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngenei...

von Strassheimer, F, Strecker, M I, Zhang, C, Mildenberger, I C, Harter, P N, Tonn, T, Steinbach, J P, Wels, W S, Burger, M C
Veröffentlicht in Neuro Oncol (2019)

P04.50 Doxycycline impairs mitochondrial function and protects human glioma cells from hypoxia-induced cell death: implications of using Tet-inducible systems

von Sauer, B, Luger, A, Lorenz, N I, Engel, A L, Braun, Y, Voss, M, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Veröffentlicht in Neuro Oncol (2018)

P14.96 Gliomatosis cerebri imaging pattern: a treatment-independent marker for worse overall survival in WHO grade II and III gliomas

von Divé, I, Steidl, E, Wagner, M, Burger, M C, Franz, K, Harter, P N, Bähr, O, Fokas, E, Herrlinger, U, Steinbach, J P
Veröffentlicht in Neuro Oncol (2019)